Show simple item record

dc.contributor.authorKaufmann, Andreas M
dc.contributor.authorStern, Peter L
dc.contributor.authorRankin, Elaine M
dc.contributor.authorSommer, Harald
dc.contributor.authorNuessler, Volkmar
dc.contributor.authorSchneider, Achim
dc.contributor.authorAdams, Malcolm
dc.contributor.authorOnon, Toli S
dc.contributor.authorBauknecht, Thomas
dc.contributor.authorWagner, Uwe
dc.contributor.authorKroon, Karlijn
dc.contributor.authorHickling, Julian K
dc.contributor.authorBoswell, Christopher M
dc.contributor.authorStacey, Simon N
dc.contributor.authorKitchener, Henry C
dc.contributor.authorGillard, Jennifer
dc.contributor.authorWanders, Jantien
dc.contributor.authorRoberts, John St C
dc.contributor.authorZwierzina, Heinz
dc.date.accessioned2009-09-24T10:15:37Z
dc.date.available2009-09-24T10:15:37Z
dc.date.issued2002-12
dc.identifier.citationSafety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. 2002, 8 (12):3676-85 Clin. Cancer Res.en
dc.identifier.issn1078-0432
dc.identifier.pmid12473576
dc.identifier.urihttp://hdl.handle.net/10541/82464
dc.description.abstractPURPOSE: Cervical cancer, the second most common malignancy in women worldwide, is almost invariably associated with infection by human papillomavirus (HPV). HPV-16 or -18 is commonly present in 70% of cervical cancers. HPV-positive tumor cells present antigens of the viral protein in the context of human leukocyte antigen (HLA) class I that can be recognized by CTLs. We have conducted a study in patients with early-stage cervical cancer to assess the safety and immunological effects of vaccination with TA-HPV, a live recombinant vaccinia virus expressing modified forms of the HPV-16 and -18 E6 and E7 proteins. EXPERIMENTAL DESIGN: Twenty-nine patients with clinical International Federation of Gynecologists and Obstetricians (FIGO) stage Ib or IIa cervical cancer were given two vaccinations with TA-HPV at least 4 weeks apart, starting 2 weeks before radical hysterectomy. Patients were monitored closely for side effects of the vaccination. Serial blood samples were examined for HPV-specific CTLs or changes in levels of antibodies to HPV-16 or -18 E6 and E7 proteins and to vaccinia virus. RESULTS: Vaccination with recombinant vaccinia was well tolerated in all patients with only mild to moderate local toxicity, and no serious adverse events were attributable to the vaccine. After a single vaccination, HPV-specific CTLs were found in four patients (HLA A1, A3, three patients; HLA A1, A24, one patient). Eight patients developed HPV-specific serological responses. CONCLUSIONS: This study confirmed the safety and immunogenicity of the vaccine in a proportion of those patients vaccinated. Additional clinical studies using TA-HPV in combination with an additional experimental vaccine for HPV-16 are currently under way.
dc.language.isoenen
dc.subjectCancer Stagingen
dc.subjectTumour Virus Infectionsen
dc.subjectUterine Cervical Canceren
dc.subject.meshAdenocarcinoma
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntibodies, Viral
dc.subject.meshCarcinoma, Squamous Cell
dc.subject.meshCervical Intraepithelial Neoplasia
dc.subject.meshDNA, Viral
dc.subject.meshDNA-Binding Proteins
dc.subject.meshFemale
dc.subject.meshGenotype
dc.subject.meshHLA-A1 Antigen
dc.subject.meshHumans
dc.subject.meshImmunoenzyme Techniques
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Staging
dc.subject.meshOncogene Proteins, Viral
dc.subject.meshPapillomaviridae
dc.subject.meshPapillomavirus Infections
dc.subject.meshPapillomavirus Vaccines
dc.subject.meshPhenotype
dc.subject.meshPolymerase Chain Reaction
dc.subject.meshPolymorphism, Single-Stranded Conformational
dc.subject.meshRepressor Proteins
dc.subject.meshSeroepidemiologic Studies
dc.subject.meshT-Lymphocytes, Cytotoxic
dc.subject.meshTumor Virus Infections
dc.subject.meshUterine Cervical Neoplasms
dc.subject.meshVaccination
dc.subject.meshVaccines, Synthetic
dc.subject.meshVaccinia virus
dc.subject.meshViral Vaccines
dc.titleSafety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.en
dc.typeArticleen
dc.contributor.departmentFrauenklinik, Friedrich-Schiller-University of Jena, 07743 Jena, Germany. a.kaufmann@med.uni-jena.deen
dc.identifier.journalClinical Cancer Researchen
html.description.abstractPURPOSE: Cervical cancer, the second most common malignancy in women worldwide, is almost invariably associated with infection by human papillomavirus (HPV). HPV-16 or -18 is commonly present in 70% of cervical cancers. HPV-positive tumor cells present antigens of the viral protein in the context of human leukocyte antigen (HLA) class I that can be recognized by CTLs. We have conducted a study in patients with early-stage cervical cancer to assess the safety and immunological effects of vaccination with TA-HPV, a live recombinant vaccinia virus expressing modified forms of the HPV-16 and -18 E6 and E7 proteins. EXPERIMENTAL DESIGN: Twenty-nine patients with clinical International Federation of Gynecologists and Obstetricians (FIGO) stage Ib or IIa cervical cancer were given two vaccinations with TA-HPV at least 4 weeks apart, starting 2 weeks before radical hysterectomy. Patients were monitored closely for side effects of the vaccination. Serial blood samples were examined for HPV-specific CTLs or changes in levels of antibodies to HPV-16 or -18 E6 and E7 proteins and to vaccinia virus. RESULTS: Vaccination with recombinant vaccinia was well tolerated in all patients with only mild to moderate local toxicity, and no serious adverse events were attributable to the vaccine. After a single vaccination, HPV-specific CTLs were found in four patients (HLA A1, A3, three patients; HLA A1, A24, one patient). Eight patients developed HPV-specific serological responses. CONCLUSIONS: This study confirmed the safety and immunogenicity of the vaccine in a proportion of those patients vaccinated. Additional clinical studies using TA-HPV in combination with an additional experimental vaccine for HPV-16 are currently under way.


This item appears in the following Collection(s)

Show simple item record